var data={"title":"Cefoxitin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefoxitin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5842?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefoxitin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefoxitin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cefoxitin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefoxitin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10327785\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mefoxin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965749\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cefoxitin For Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147719\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Second Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147677\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections:</b> IV: 1 to 2 g every 6 to 8 hours (IM injection is painful); up to 12 g daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal) (off-label use):</b> IV: 1 g every 6 to 8 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gas gangrene:</b> IV: 2 g every 4 hours or 3 g every 6 hours (maximum daily dosage: 12 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated, community acquired, mild-to-moderate (Solomkin 2010):</b> IV: 2 g every 6 hours for 4 to 7 days (provided source controlled)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Moderately severe or severe infections:</b> IV: 1 g every 4 hours or 2 g every 6 to 8 hours (maximum daily dosage: 8 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mycobacterium abscessus</i>, not MTB or MAI (off-label use; Griffith 2007):</b> IV: 12 g daily in divided doses with concomitant amikacin for &ge;14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (CDC [Workowski 2015]): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inpatients:</i> IV: 2 g every 6 hours <b>plus</b> doxycycline for at least 24 to 48 hours after clinical improvement, followed by oral doxycycline to complete 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Outpatients:</i> IM: 2 g as a single dose <b>plus</b> oral probenecid, followed by oral doxycycline (with or without concomitant metronidazole) for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling (procedures other than Cesarian section):</i> IV: 2 g 30 to 60 minutes prior to surgical incision, followed by 2 g every 6 hours for no more than 24 hours after surgery depending on the procedure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cesarean section:</i> IV: 2 g as soon as umbilical cord is clamped as a single dose <b>or</b> 2 g as soon as umbilical cord is clamped followed by 2 g at 4 and 8 hours after the initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations:</i> 2 g within 60 minutes prior to surgical incision. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uncomplicated cutaneous, urinary tract, lung infections:</b> IV: 1 g every 6&ndash;8 hours (maximum daily dosage: 4 g daily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147699\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cefoxitin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefoxitin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &gt;3 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> IV: 80 to 160 mg/kg/day divided every 4 to 6 hours (maximum daily dose: 12 <b>g daily</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations (Red Book [AAP] 2012):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Mild-to-moderate infection:</b> IV: Infants &gt;3 months and Children: 80 mg/kg/day in divided doses every 6 to 8 hours (maximum daily dose: 4000 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Severe infection:</b> IV: Infants &gt;3 months and Children: 160 mg/kg/day in divided doses every 4 to 6 hours (maximum daily dose: 12 <b>g daily</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &gt;3 months and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical (perioperative) prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> IV: 30 to 40 mg/kg 30 to 60 minutes prior to surgical incision followed by 30 to 40 mg/kg/dose every 6 hours for no more than 24 hours after surgery depending on the procedure </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Alternative recommendations:</i> Children &ge;1 year: IV: 40 mg/kg within 60 minutes prior to surgical incision (maximum: 2000 mg per dose). Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Surgical (perioperative) prophylaxis:</b>  Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147678\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147679\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loading dose: 1 to 2 g, followed by maintenance dosing according to CrCl.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maintenance dosage:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute: 1 to 2 g every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 29 mL/minute: 1 to 2 g every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 5 to 9 mL/minute: 0.5 to 1 g every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;5 mL/minute: 0.5 to 1 g every 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Loading dose: 1 to 2 g after each hemodialysis; maintenance dose as noted above based on creatinine clearance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682542\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147652\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mefoxin: 1 g (50 mL [DSC]); 2 g (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147636\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147656\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Inject deep IM into large muscle mass. <b>Note:</b> IM injection is painful and this route of administration is not described in the prescribing information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Can be administered IVP over 3 to 5 minutes or by IV intermittent infusion over 10 to 60 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147655\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone and joint infections:</b> Treatment of bone and joint infections caused by <i>Staphylococcus aureus</i> (including penicillinase-producing strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gynecological infections:</b> Treatment of endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by <i>Escherichia coli</i>, <i>Neisseria gonorrhoeae</i> (including penicillinase-producing strains), <i>Bacteroides</i> species including <i>Bacteroides fragilis</i>, <i>Clostridium</i> species, <i>P. niger</i>, <i>Peptostreptococcus</i> species, and <i>Streptococcus agalactiae</i>. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections:</b> Treatment of peritonitis and intra-abdominal infections or abscess, caused by <i>E. coli</i>, <i>Klebsiella</i> species, <i>Bacteroides</i> species (including <i>B. fragilis</i>), and <i>Clostridium</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections:</b> Treatment of pneumonia and lung abscess, caused by <i>Streptococcus pneumoniae</i>, other streptococci (excluding enterococci; eg, <i>Enterococcus faecalis</i> [formerly <i>Streptococcus faecalis</i>]), <i>S. aureus</i> (including penicillinase-producing strains), <i>E. coli</i>, <i>Klebsiella</i> species, <i>Haemophilus influenzae</i>, and <i>Bacteroides</i> species. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative prophylaxis:</b> Prophylaxis of infection in patients undergoing uncontaminated GI surgery, abdominal or vaginal hysterectomy, or cesarean section.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septicemia:</b> Treatment of septicemia caused by <i>S. pneumoniae</i>, <i>S. aureus</i> (including penicillinase-producing strains), <i>E. coli</i>, <i>Klebsiella</i> species, and <i>Bacteroides</i> species including <i>B. fragilis</i>. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections caused by <i>S. aureus</i> (including penicillinase-producing strains), <i>Staphylococcus epidermidis</i>, <i>Streptococcus pyogenes</i> and other streptococci (excluding enterococci [eg, <i>E. faecalis</i>] [formerly <i>S. faecalis</i>]), <i>E. coli</i>, <i>Proteus mirabilis</i>, <i>Klebsiella</i> species, <i>Bacteroides</i> species including <i>B. fragilis</i>, <i>Clostridium</i> species, <i>P. niger</i>, and <i>Peptostreptococcus</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections:</b> Treatment of UTIs caused by <i>E. coli</i>, <i>Klebsiella</i> species, <i>P. mirabilis</i>, <i>Morganella morganii</i>, <i>Proteus vulgaris</i>, and <i>Providencia</i> species (including <i>Providencia rettgeri</i>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use:  Cefoxitin does not have activity against <i>Chlamydia trachomatis</i>.  When cefoxitin is used to treat pelvic inflammatory disease, add appropriate antichlamydial coverage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28575360\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bite wounds (animal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147726\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefOXitin may be confused with ceFAZolin, cefotaxime, cefoTEtan, cefTAZidime, cefTRIAXone, Cytoxan </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mefoxin may be confused with Lanoxin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147643\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: Gastrointestinal: Diarrhea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%: Anaphylaxis, angioedema, bone marrow depression, dyspnea, eosinophilia, exacerbation of myasthenia gravis, exfoliative dermatitis, fever, hemolytic anemia, hypotension, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, interstitial nephritis, jaundice, leukopenia, nausea, nephrotoxicity (increased; with aminoglycosides), phlebitis, prolonged prothrombin time, pruritus, pseudomembranous colitis, skin rash, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, urticaria, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147659\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefoxitin, any component of the formulation, or other cephalosporins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147640\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria). If a hypersensitivity reaction occurs, discontinue immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; GI disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Children: In pediatric patients &ge;3 months of age, higher doses have been associated with an increased incidence of eosinophilia and elevated AST.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased renal function; use care in dose selection and monitor renal function. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Discontinuation of therapy: For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298992\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147645\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9223&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5953484\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Peak serum concentrations of cefoxitin during pregnancy may be similar to or decreased compared to nonpregnant values. Maternal half-life may be shorter at term. Pregnancy-induced hypertension increases trough concentrations in the immediate postpartum period. Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147661\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Very small amounts of cefoxitin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefoxitin to nursing women. Nondose-related effects could include modification of bowel flora. Cefoxitin pharmacokinetics may be altered immediately postpartum.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147662\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147650\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal function periodically when used in combination with other nephrotoxic drugs; prothrombin time. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147639\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147658\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to body tissues and fluids including ascitic, pleural, synovial, bile; poorly penetrates into CSF even with inflammation of the meninges (Landesman 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 65% to 79% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Neonates and Infants (PNA: 10-53 days): 1.4 hours (Regazzi 1983); Adults: 41-59 minutes; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: Within 20-30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (85% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323049\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefOXitin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefOXitin Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $3.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $7.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefOXitin Sodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g 4% (1): $13.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g 2.2% (1): $24.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038555\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aboxitin (BD);</li>\n      <li>Acifox (PH);</li>\n      <li>Cefmore (TW);</li>\n      <li>Cefovex (PH);</li>\n      <li>Cefoxitin Sodium (AU);</li>\n      <li>Cefoxivit (PH);</li>\n      <li>Cefxitin (TH);</li>\n      <li>Cenomycin (JP);</li>\n      <li>Daliding (CN);</li>\n      <li>Dintaxin (PH);</li>\n      <li>Foxitane (BD);</li>\n      <li>Foxitin (AE, JO, QA, SA);</li>\n      <li>Irva (BD);</li>\n      <li>Jeitin (KR);</li>\n      <li>Lofatin (TW);</li>\n      <li>Mefoxil (GR);</li>\n      <li>Mefoxin (AE, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CY, CZ, EG, ET, FI, FR, GB, GH, GM, GN, GY, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NZ, OM, PT, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Mefoxitin (AT, CH, DE, DK, NO, SE);</li>\n      <li>Merxin (JP);</li>\n      <li>Monodin (PH);</li>\n      <li>Monowel (PH);</li>\n      <li>Pacetin (KR);</li>\n      <li>Panafox (PH);</li>\n      <li>Sephros (MY);</li>\n      <li>Voxitin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zepax (PH);</li>\n      <li>Zepotin (PH);</li>\n      <li>Zoxin (JO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Antibacterial Drugs Dosage Tables. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds; American Academy of Pediatrics. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Med Lett Drugs Ther</i>, 1993, 35(906):91-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/8371696/pubmed\" target=\"_blank\" id=\"8371696\">8371696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al, &ldquo;Antimicrobial Prophylaxis for Surgery: An Advisory Statement From the National Surgical Infection Prevention Project,&rdquo; <i>Clin Infect Dis</i>, 2004, 38(12):1706-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/15227616/pubmed\" target=\"_blank\" id=\"15227616\">15227616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldman WE, Moffitt S, and Sprow N, &ldquo;Clinical and Pharmacokinetic Evaluation of Parenteral Cefoxitin in Infants and Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1980, 17(4):669-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/7396456/pubmed\" target=\"_blank\" id=\"7396456\">7396456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia MJ, Garcia A, Nieto MJ, et al, &ldquo;Disposition of Cefoxitin in the Elderly,&rdquo; <i>Int J Clin Pharmacol Ther Toxicol</i>, 1980, 18(11):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/7203727/pubmed\" target=\"_blank\" id=\"7203727\">7203727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. <i>Am J Respir Crit Care Med</i>. 2007;175(4):367-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/17277290/pubmed\" target=\"_blank\" id=\"17277290\">17277290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landesman SH, Corrado ML, Shah PM, Armengaud M, Barza M, Cherubin CE. Past and current roles for cephalosporin anitbiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. <i>Am J Med</i>. 1981;71(4):693-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/6269429/pubmed\" target=\"_blank\" id=\"6269429\">6269429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mefoxin (cefoxitin) [prescribing information]. Rockford, IL: Mylan Institutional LLC; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regazzi MB, Chirico G, Cristiani D, et al, &ldquo;Cefoxitin in Newborn Infants. A Clinical and Pharmacokinetic Study,&rdquo; <i>Eur J Clin Pharmacol</i>, 1983, 25(4):507-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/6653646/pubmed\" target=\"_blank\" id=\"6653646\">6653646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefoxitin-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9223 Version 150.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10327785\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14965749\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F147719\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F147677\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F147699\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F147678\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F147679\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682542\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147652\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F147636\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F147656\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F147655\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28575360\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147726\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147643\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147659\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147640\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298992\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147645\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5953484\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F147661\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F147662\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F147650\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147639\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F147658\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323049\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038555\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9223|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefoxitin-patient-drug-information\" class=\"drug drug_patient\">Cefoxitin: Patient drug information</a></li><li><a href=\"topic.htm?path=cefoxitin-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefoxitin: Pediatric drug information</a></li></ul></div></div>","javascript":null}